BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

National Institute for Clinical Excellence (NICE) Backs Leukemia Drug Tasigna After Novartis AG Agrees to Discount


8/18/2011 8:32:59 AM

Leukaemia drug Tasigna has been backed by Britain's healthcare cost watchdog after its maker Novartis agreed to discount the treatment's cost of more than 30,000 pounds per patient per year. The National Institute for Health and Clinical Excellence (NICE) had previously rejected Tasigna, along with Bristol-Myers Squibb's similarly priced product Sprycel, for treating chronic myeloid leukaemia on the state-funded National Health Service. It also said in draft guidance in May that it was not able to recommend high-dose Glivec, another Novartis drug for chronic myeloid leukaemia, following a price increase.

Read at Reuters
Read at InPharm.com
Read at Telegraph

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES